Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments

2 years ago

An ongoing phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened; Results are expected by…

EDAP to Announce Fourth Quarter and Full-Year 2023 Financial Results on March 27, 2024

2 years ago

Company to host conference call and webcast on Wednesday, March 27th at 8:30am EDT LYON, France, March 13, 2024 --…

ProQR Announces Year End 2023 Operating and Financial Results

2 years ago

Preclinical and translational pipeline program data for AX-0810 for Cholestatic Diseases targeting NTCP and AX-1412 for Cardiovascular Disease targeting B4GALT1…

ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

2 years ago

ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $16.6 million in 4Q 2023 and $69.1 million for full year (FY) 2023; 4Q…

Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025

2 years ago

STAFFORD, Texas, March 13, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused…

FendX Announces Warrant Exercises and Share for Debt Settlement

2 years ago

Oakville, Ontario--(Newsfile Corp. - March 13, 2024) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the "Company" or…

BioNxt Reports Successful Results From ODF Cladribine PK Study

2 years ago

VANCOUVER, BC / ACCESSWIRE / March 13, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to…

Bioz and Teledyne LABS Announce AI-Powered Partnership Enabling Easy Access to Product Citations From Scientific Publications

2 years ago

PALO ALTO, CA / ACCESSWIRE / March 13, 2024 / Bioz, Inc., an AI company specializing in the analysis of…

Kuros Reports 163% Growth in Direct MagnetOs Sales and 153% Increase in Total Medical Device Sales for the Full Year 2023

2 years ago

Financial highlightsDirect MagnetOs sales grew by 163% to CHF 31.7 million in 2023, climbing from CHF 12.1 million in 2022.…

GE HealthCare Technologies Inc. Prices Upsized Secondary Offering of 14,000,000 Shares

2 years ago

CHICAGO--(BUSINESS WIRE)--GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the pricing of the previously announced…